Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	18541
Country	Türkiye

Received	2015-04-23 08:38
Peer-Review Started	2015-04-24 15:23
To Make the First Decision	2015-06-26 17:31
Return for Revision	2015-09-02 15:40
Revised	2015-10-06 17:01
Second Decision	2015-11-27 15:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-12-08 14:55
Articles in Press	2015-12-08 14:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-08 20:52
Publish the Manuscript Online	2016-01-14 20:17

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Hakan Kocoglu, Fatih Mehmet Velibeyoglu, Mustafa Karaca and Deniz Tural
Funding Agency and Grant Number
Corresponding Author	Deniz Tural, MD, Department of Medical Oncology, Bakirkoy Education and Research Hospital, Zuhuratbaba District, Tevfik Saglam Street, No: 11, 34900 Istanbul, Turkey. deniztural@gmail.com
Key Words	Colorectal cancer; Epidermal growth factor receptor; KRAS mutation; Anti-epidermal growth factor receptor antibody; Drug resistance
Core Tip	Molecular targeting agents, such as monoclonal antibodies against epidermal growth factor receptor (anti-EGFR), provide additional clinical benefits in metastatic colorectal cancer (CRC). However, anti-EGFR therapies have limited usage due to approximately 95% of patients with KRAS mutated metastatic CRC do not response to anti-EGFR treatment. Thus, KRAS mutation is predictive of nonresponse to anti-EGFR therapies but it alone is not a sufficient basis to decide who should not be received such therapies because approximately fifty percent (40%-60%) of CRC patients with wild-type KRAS mutation also have poor response to anti-EGFR based treatment. This fact leads us to suspect that there must be other molecular determinants of response to anti-EGFR therapies which have not been identified yet. Current article summarizes the clinical efficacy of anti-EGFR therapies and also evaluates its resistance mechanisms.
Publish Date	2016-01-14 20:17
Citation	Kocoglu H, Velibeyoglu FM, Karaca M, Tural D. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. World J Gastrointest Oncol 2016; 8(1): 1-7
URL	http://www.wjgnet.com/1948-5204/full/v8/i1/1.htm
DOI	http://dx.doi.org/10.4251/wjgo.v8.i1.1

Full Article (PDF)	WJGO-8-1.pdf
Full Article (Word)	WJGO-8-1.doc
Manuscript File	18541-Review.docx
Answering Reviewers	18541-Answering reviewers.pdf
Audio Core Tip	18541-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	18541-Conflict-of-interest statement.pdf
Copyright License Agreement	18541-Copyright assignment.pdf
Peer-review Report	18541-Peer-review(s).pdf
Scientific Misconduct Check	18541-Scientific misconduct check.pdf
Scientific Editor Work List	18541-Scientific editor work list.pdf